MARKET NEWS

Roivant and Pfizer Unveil Priovant Therapeutics & Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
WuXi STA Opens A High-Potency API Plant
Verrica Pharmaceuticals Holds Type A Meeting With FDA for VP-102 for Molluscum Contagiosum
Akoya Biosciences to Partner With Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature Test Into a Companion Diagnostic
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
Artelo Biosciences Presents Positive Pre-Clinical Results for Novel FABP5 Inhibitor

  FEATURED EDITORIAL

  COMPANY PROFILE

At Lonza Small Molecules, our connected experts work together to provide contract development and manufacturing services, helping pharma and small biotech companies deliver their medicines to patients in need. From the earliest stages of discovery to the final drug product, we can simplify your outsourcing experience with our reliable, timely service, anticipating risks and solving problems. Whether you are developing a pioneering therapy or creating a new oral solid dosage form, Lonza is the only CDMO partner you need. Throughout your molecule’s journey from early development to commercial product, we work as one. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Norstella & Citeline Unite to Offer Life Sciences Clients a Full Suite of Commercial & Clinical Solutions

Norstella & Citeline Unite to Offer Life Sciences Clients a Full Suite of Commercial & Clinical Solutions

Norstella and Citeline (formerly Pharma Intelligence) have recently announced an agreement to merge the companies. By uniting Norstella, which is composed of four prominent pharmaceutical solutions providers….

Terumo Blood and Cell Technologies & GenCure Collaborate to Advance Cell & Gene Therapy Manufacturing Solutions

Terumo Blood and Cell Technologies & GenCure Collaborate to Advance Cell & Gene Therapy Manufacturing Solutions

Terumo Blood and Cell Technologies recently announced it has signed a new collaborative agreement with GenCure, a subsidiary of BioBridge Global, to extend and unify cell and gene therapy manufacturing solutions…..

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration With ONO Pharmaceutical

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration With ONO Pharmaceutical

Fate Therapeutics, Inc. recently announced it has expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co., Ltd. to include the development of….

Vetter’s Newest Clinical Manufacturing Site Successfully Completed its First Customer Fills

Vetter’s Newest Clinical Manufacturing Site Successfully Completed its First Customer Fills

With the realization of the first successful customer fills, Vetter has reached another milestone at its new clinical manufacturing facility in Rankweil, Austria. Further batches are already planned,….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations. It shows the over-additive effect of using two excipients together and addresses how excipients’ viscosity-reducing ability depends on pH. The results show the effect of protein viscosity on …

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

Nanoparticles offer multi-functional capabilities that include the ability to be tracked within the body, deliver a specific compound at a controlled rate, target a particular location, and remotely kill cells once in place due to which their use as drug …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 6 – Inhalation Delivery
July 13 – Bioavailability